Brian Skorney
Stock Analyst at Baird
(3.33)
# 2,041
Out of 5,180 analysts
119
Total ratings
43.53%
Success rate
4.41%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $22 → $41 | $23.41 | +75.14% | 5 | Mar 18, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $56.69 | +71.11% | 2 | Mar 9, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $94.62 | -7.00% | 6 | Dec 9, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $22.13 | -32.22% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $36.57 | +69.54% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $9.62 | +440.54% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $132.56 | +40.31% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $36.99 | +227.12% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $18.10 | +76.80% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $183.78 | +38.75% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $777.25 | -24.48% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $140.30 | -28.72% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $11.01 | +172.48% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $12.97 | +54.20% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $22.73 | +9.99% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $353.28 | -39.14% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.67 | +393.83% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.63 | +351.91% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $447.26 | -27.34% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $25.10 | -60.16% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.60 | +44,855.04% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.99 | +50.38% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.53 | +56,185.18% | 3 | May 7, 2018 |
Alto Neuroscience
Mar 18, 2026
Maintains: Outperform
Price Target: $22 → $41
Current: $23.41
Upside: +75.14%
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $56.69
Upside: +71.11%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $94.62
Upside: -7.00%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $22.13
Upside: -32.22%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $36.57
Upside: +69.54%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $9.62
Upside: +440.54%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $132.56
Upside: +40.31%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $36.99
Upside: +227.12%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $18.10
Upside: +76.80%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $183.78
Upside: +38.75%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $777.25
Upside: -24.48%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $140.30
Upside: -28.72%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $11.01
Upside: +172.48%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $12.97
Upside: +54.20%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $22.73
Upside: +9.99%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $353.28
Upside: -39.14%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.67
Upside: +393.83%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.63
Upside: +351.91%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $447.26
Upside: -27.34%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $25.10
Upside: -60.16%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.60
Upside: +44,855.04%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.99
Upside: +50.38%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.53
Upside: +56,185.18%